Oncolytic MV can be fully genetically retargeted to specified cell surface receptors by elongating the attachment protein with designed ankyrin repeat protein.120 It can be also retargeted by modification of viral H-glycoprotein which is also responsible for interaction with cell receptors.121 The retargeting approach allows creating panels of oncolytic viruses with different targeting specificity, which is particularly useful for treating cancer cells that have lost expression of conventional receptors. Here, CD177 is linked to cancer.